Type 1 Diabetes
Our NICHE® platform is designed to restore insulin production through precision cell delivery
Engineered to overcome the barriers to cell therapy
Our NICHE (Neovascularized Implantable Cell Homing and Encapsulation) platform is an implantable combination product designed to simultaneously address multiple barriers to cell therapy by creating a vascularized, immune-protected microenvironment that nurtures transplanted insulin-producing cells.
A localized immunomodulation reservoir
A surrounding reservoir that delivers immunomodulatory agents directly to the graft microenvironment, helping protect transplanted cells from immune rejection while minimizing systemic exposure.
A prevascularized central reservoir
This reservoir houses transplanted insulin-producing cells and supports their survival by enabling direct vascular integration with the host blood supply.
By combining vascular support with localized immune protection, the NICHE platform is designed to enable reliable insulin production without the need for lifelong systemic immunosuppression.
Promising preclinical data
Why Type 1 diabetes still demands more
What has held cell therapy back
Cell replacement therapies offer the potential to restore natural insulin production, but biological barriers have limited their success. These include immune rejection, inadequate vascularization, and loss of cell function over time. Historically, efforts to overcome these barriers have often depended on chronic systemic immunosuppression. Solving these challenges requires both vascular support and immune protection at the site of transplantation.5
Enabling what cell therapy can become
The NICHE platform represents more than a solution for Type 1 diabetes. By solving the fundamental challenges of vascularization and immune protection, it lays the groundwork for a new generation of cell-based therapies, one where the body's own biology becomes a partner in treatment.
Ready to explore what NICHE could do for your therapy?
Healthy Pancreatic islet